SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that the Company will host a live conference call and webcast in conjunction with its CAR T Breakfast Teach-In on Thursday, November 29, 2018 at 7:30 a.m. EST in New York, NY.
The event features next generation CAR T experts:
- Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center (MSK)
- Marco Davila, M.D., Ph.D., Associate Attending Physician, Department of Blood & Marrow Transplantation and Cellular Immunotherapy Medical Director, Cell Therapy Facility, Moffitt Cancer Center
Analysts and investors can participate in the event via conference call by dialing (888) 540-6216 for domestic callers and (734) 385-2715 for international callers, using the conference ID 8898797. The live webcast can be accessed on the Investors and Media section of Atarabio.com. A replay of the webcast will be available on the Company’s website for 30 days following the live conference call.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s most advanced T-cell immunotherapy, tab-cel® (tabelecleucel), is in Phase 3 development for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC). Atara is also developing T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis (MS). Atara's pipeline also includes next generation chimeric antigen receptor T-cell (CAR T) immunotherapies for patients with hematologic and solid tumors, autoimmune and infectious diseases. The company was founded in 2012 and is headquartered in South San Francisco, California.
INVESTOR & MEDIA CONTACTS:
Investors:
John Craighead, Atara Biotherapeutics
650-410-3012
jcraighead@atarabio.com
John Grimaldi, Burns McClellan
212-213-0006 x362
jgrimaldi@burnsmc.com
Media:
Nancie Steinberg, Burns McClellan
212-213-0006 x318
nsteinberg@burnsmc.com